Carpal Tunnel

Carpal Tunnel Syndrome: A Natural-Health and Nutrition Reference

Definition and Overview

Carpal tunnel syndrome (CTS) is the most frequent of the compressive syndromes and is defined by compression and/or traction of the median nerve at wrist level. It is the most common mononeuropathy and can be caused by thickened ligaments and tendon sheaths. The main cause of CTS is increased pressure within the carpal tunnel, which consequently applies compressive force to the median nerve, causing nerve ischemia — the source of the motor and sensory dysfunction experienced by patients.

Globally, CTS affects approximately 1–5% of the general population, with studies indicating a higher prevalence in females, ranging from 7–9%, compared to males, who have an estimated prevalence of 0.6%. CTS is more prevalent in females than males, with a 3:1 female-to-male ratio.

Anatomy: The Carpal Tunnel and Median Nerve

The carpal tunnel is an anatomical compartment located at the base of the palm. Nine flexor tendons and the median nerve pass through the carpal tunnel, which is surrounded on three sides by the carpal bones that form an arch. The roof of the carpal tunnel is formed by the flexor retinaculum (also known as the transverse carpal ligament), a thick connective tissue ligament that bridges the space between the medial and lateral ends of the carpal arch, converting the arch into a tunnel.

The floor of the carpal tunnel is formed by the carpal groove (or carpal arch), a deep arch formed by the palmar aspect of the carpal bones. This arch is bounded medially by the pisiform bone and the hook of the hamate, and laterally by the tubercles of the scaphoid and trapezium bones. Because these boundaries are very rigid, the carpal tunnel has little capacity to stretch or increase in size.

The median nerve originates as a group of nerve roots in the neck that come together to form a single nerve in the arm, which travels down the upper arm, across the elbow, and into the forearm, then passes through the carpal tunnel at the wrist on its way to the hand and fingers. The median nerve provides feeling or sensation to the thumb, index finger, long finger, and half of the ring finger. At the level of the wrist, the median nerve supplies the muscles at the base of the thumb that allow it to abduct, move away from the other four fingers, as well as move out of the plane of the palm.

Anatomically, there are two sites of median nerve compression: one at the level of the proximal limit of the carpal tunnel, caused by wrist flexion because of changes in thickness and stiffness of the forearm fascia and in the proximal portion of the flexor retinaculum; and the second at the level of the narrowest portion, close to the hamate hook.

Clinical Presentation

The typical initial signs of CTS include pain, numbness, and paresthesias, which affect the first three digits and the lateral half of the fourth digit. Symptoms can exhibit variability, with pain manifesting at the wrist, involving the entire hand, and potentially radiating up the forearm or extending beyond the elbow.

If left untreated, CTS can cause weakness and atrophy of the thenar muscles. Clinical features include numbness, tingling, and pain in the distribution of the median nerve. The pain will usually radiate to the forearm. Symptoms are often associated with waking the patient from their sleep and being worse in the mornings.

The initial symptoms of CTS typically include nocturnal paresthesias. Over time, the paresthesias become more persistent, gradually increasing in both intensity and frequency. Sensory deficits in the median nerve distribution may include a diminished ability to feel light touch or temperature. In parallel, motor symptoms emerge, notably weakness of the thenar muscles, which impairs the coordination and strength of the thumb, further limiting hand function in everyday tasks.

Body Systems Involved

CTS is fundamentally a disorder of the peripheral nervous system, specifically the median nerve, but it intersects with multiple organ systems:

• Musculoskeletal system: The median nerve branches to give off a recurrent branch providing motor innervation to the thenar muscles — the abductor pollicis brevis, the flexor pollicis brevis, and the opponens pollicis. It also gives off digital cutaneous branches supplying sensory innervation to the first three digits and half of the fourth digit on the palmar side, and motor innervation to the first and second lumbricals of the hand.
• Endocrine system: Hormonal risk factors include diabetes, hypothyroidism, the use of combined oral contraceptives, hormonal replacement therapy, and corticosteroid use in the absence of inflammatory arthritis.
• Metabolic system: Obesity likely contributes to CTS through increased adipose deposition in the carpal tunnel, elevating intracarpal pressure. Diabetes mellitus, through microvascular damage, nerve ischemia, and glycation-related connective tissue changes, may exacerbate CTS risk and severity.
• Immune and inflammatory systems: Visceral adipose cells secrete IL-6 and plasminogen activator inhibitor 1, have an unbalanced adipokine profile — with higher leptin and resistin and lower adiponectin — and a different pattern of proteins, all of which link metabolic dysregulation to local and systemic inflammatory conditions relevant to nerve compression.

Contributing and Associated Factors

Demographic and Anatomical Factors

Risk factors for CTS include repetitive hand movements in occupations that require typing, certain anatomical and physiological characteristics (e.g., smaller carpal tunnel size), age (risk increases with age), gender (higher risk in women), pregnancy, medical conditions (e.g., obesity, diabetes, arthritis, metabolic syndrome), and previous trauma or injury to the wrist.

Heredity is likely an important factor. The carpal tunnel may be naturally smaller in some people, or there may be anatomic differences that change the amount of space for the nerve — and these traits can run in families.

CTS is also more prevalent in females, especially between the ages of 40 and 60, with symptom onset occurring significantly earlier in females compared to males.

Occupational and Mechanical Factors

Occupations involving frequent exposure to vibrating equipment or repetitive movements significantly elevate the risk of developing CTS. Notable ecological risk factors include extended positions in excess of wrist flexion or extension, monotonous use of the flexor muscles, and exposure to vibration.

Physical labour, working in pain, and certain comorbidities were found in a systematic review to be strongly associated with an increased risk of developing CTS.

Medical Comorbidities

Numerous medical conditions contribute to an increased prevalence of CTS. These include pregnancy, hypothyroidism, diabetes mellitus, and certain rare disorders, such as mucopolysaccharidoses, mucolipidoses, and acromegaly, as well as a history of distal radius fractures.

The prevalence of CTS is reported to be more prevalent in diabetes mellitus patients compared to the normal population. Carpal tunnel syndrome is very common among acromegaly patients and often accounts for the initial symptom; the incidence of CTS ranges from 25% to 64% in the presence of acromegaly.

Obesity, Metabolic Syndrome, and Diabetes

The risk of developing CTS is doubled in individuals who are obese. A Mendelian randomization study using genome-wide association data provided causal evidence: univariable Mendelian randomization indicated a positive correlation of BMI with CTS risk (OR 1.66, 95% CI 1.39–1.97). Genetically proxied type 2 diabetes also significantly increased the risk of CTS (OR 1.17, 95% CI 1.07–1.29). The causal effect of BMI and T2D on CTS remained consistent after adjusting for each other with multivariable Mendelian randomization.

Smoking

In a large case-control study among a Chinese population, the odds ratio for smoking as a risk factor for CTS was 4.862 (95% CI 3.991–5.925), representing a substantially elevated association compared with non-smokers. The mechanisms are likely multifactorial, involving vascular and neural effects of nicotine and combustion products.

Hormonal Factors

A case-control analysis found repetitive motion, past hysterectomy without oophorectomy, recent menopause, and higher body-mass index to be positively associated with CTS. Pregnancy-related hormonal changes, previous wrist injuries, anatomical variations in the carpal tunnel, and medical conditions such as rheumatoid arthritis and hypothyroidism can contribute to the development of CTS.

Nutrients, Herbs, and Natural Ingredients

Vitamin B6 (Pyridoxine)

Traditional and Historical Context

The interest in pyridoxine for CTS emerged largely from clinical observations in the 1970s and 1980s by researchers including Ellis, Folkers, and colleagues, who noted low vitamin B6 status in CTS patients. This research context — rather than a distinct ethnomedicine tradition — framed the early use of B6 supplementation as a conservative, nutritionally oriented intervention for CTS.

Scientific Evidence

The specific activities and percentage deficiencies of the glutamic oxaloacetic transaminase of erythrocytes (EGOT) were determined for CTS patients diagnosed by clinical examination and electrical conduction data; the EGOT data revealed a severe deficiency of vitamin B6. After double-blind treatment with pyridoxine and placebo, two physicians identified those receiving pyridoxine (clinically improved) and those receiving placebo (did not improve) without error (P < 0.0078).

A randomized study of 40 CTS patients assigned a case group of 20 subjects receiving vitamin B6 (120 mg/day for 3 months) plus splinting, and a control group of 19 subjects receiving splinting only; daily symptoms and electrodiagnostic (NCV-EMG) results were assessed at baseline and after 3 months. The study suggested that vitamin B6 treatment improves clinical symptoms and sensory electrodiagnostic results in CTS patients.

Spooner et al. observed that the most discouraging symptoms — pain, numbness, and tingling at night — were not alleviated in patients given 200 mg of pyridoxine for 12 weeks. In a retrospective review of 994 CTS patient charts, Kasdan and Janes found that in the 494 patients whose treatment included vitamin B6 (100 mg twice daily), the rate of symptom alleviation was much higher (68%) than among patients who did not receive vitamin B6.

The literature does not give convincing evidence for use of pyridoxine as the sole treatment when confronted with a patient with idiopathic CTS. It may be of value as an adjunct in conservative therapy through altered perception of pain and increased pain threshold. Overall, the evidence for pyridoxine in CTS is mixed and methodologically inconsistent; results vary considerably across studies, and high-quality large-scale RCTs are lacking.

The recommended daily intake of vitamin B6 is 2 mg or less for all age, sex, and life-stage groups, and the upper limit has been set at 100 mg/day. Pyridoxine's main toxicity symptom is sensory neuropathy. Most studies indicate that no neuropathy is brought on by doses between 40 and 500 mg/day, so the lowest observed adverse effect level has been established at 500 mg/day.

Vitamin D (Cholecalciferol)

Traditional Use

Vitamin D has no specific ethnomedicinal tradition in relation to CTS. Interest developed from the observation of widespread deficiency in CTS cohorts and from the known roles of vitamin D in neurological function and inflammation.

Scientific Evidence

Emerging evidence suggests a potential link between vitamin D status and CTS incidence and severity, with vitamin D deficiency proposed as an independent risk factor influencing symptom severity.

One observational study found that vitamin D deficiency was considerably more prevalent in patients with CTS (95.8%) compared with controls (22.9%). However, not all studies have confirmed this association. Lee et al. showed there was no difference in vitamin D levels between CTS patients and controls, illustrating the inconsistency in the observational evidence base.

A systematic review published in the Journal of Experimental Orthopaedics searched PubMed, Cochrane Library, Scopus, and Web of Science (2000–2021) and retrieved four eligible studies: treatment outcomes were evaluated by visual analog scale (124 wrists), functional scores (176 patients), muscle strength (84 patients), and nerve conduction velocity (216 wrists). After vitamin D supplementation, two studies reported improved pain scores and nerve conduction velocity, and three studies showed enhancement of functional status. Vitamin D administration could offer favorable outcomes in pain improvement, better functional status, and increased sensory conduction velocity in CTS; however, there are to date no recommendations concerning a standardized dose or duration.

A second systematic review (19 articles) concluded that vitamin D supplementation can improve symptoms in CTS patients, and low serum 25(OH)D can aggravate the symptoms and could be a risk factor for its occurrence; however, more observational studies and clinical trials are needed. The body of evidence is currently preliminary to moderate: observational data are suggestive, but large RCTs are still needed.

Alpha-Lipoic Acid (ALA)

Traditional Use

Alpha-lipoic acid has no established use in pre-modern or ethnomedicinal traditions as a remedy for CTS. Its investigation in this context is entirely a product of modern biochemical research into its antioxidant and neuroprotective properties.

Scientific Evidence

Alpha-lipoic acid is an endogenous antioxidant with established use in diabetic peripheral neuropathy in some European countries, and has been studied in CTS given the shared mechanism of oxidative nerve stress.

One study compared the efficacy of ALA 600 mg/day combined with gamma-linolenic acid (GLA) 360 mg/day, versus a multivitamin B preparation (B6 150 mg, B1 100 mg, B12 500 mcg daily) for 90 days in 112 subjects with moderately severe CTS, assessing outcomes by the Boston Questionnaire, Hi-Ob scale, and electromyography.

A randomized, double-blind, placebo-controlled clinical trial in 20 adults with idiopathic CTS administered 600 mg ALA or placebo per day for 1 month before surgery and 2 months afterward, assessing clinical and neurophysiological outcomes.

In another double-blind RCT, 64 patients with CTS were randomly assigned to surgical decompression followed by ALA for 40 days, or decompression followed by placebo. Alpha-lipoic acid did not improve nerve conduction velocity or Boston Carpal Tunnel score significantly; however, a statistically significant reduction in the postoperative incidence of pillar pain was noted in the ALA group.

A systematic review and meta-analysis of six RCTs found: five RCTs were included in the final meta-analysis. Most subjects were females aged 45–69 years. Boston Carpal Tunnel Questionnaire score, median motor nerve distal latency, and Visual Analog Scale all showed significant improvement in the ALA group. There was no significant improvement in median sensory nerve conduction. Postoperative ALA supplementation may be beneficial in improving the clinical function of CTS; ALA improved motor distal latency but did not affect sensory nerve conduction velocity.

A 2025 double-blind RCT evaluated a combination: participants were randomly assigned to either treatment (n=37) or placebo (n=33). The treatment group received alpha-lipoic acid (300 mg), methylcobalamin (500 mcg), vitamin B1 (39 mg), and vitamin B6 (8 mg) twice daily for 6 months; patients were evaluated at baseline, 3 months, and 6 months.

Overall, the evidence for ALA in CTS is moderate and growing, particularly for combined perioperative supplementation, but most trials are small and heterogeneous. Evidence is stronger for motor than sensory outcomes, and most robust in the surgical context.

Curcumin (from Turmeric, Curcuma longa)

Traditional Use

Turmeric (Curcuma longa) has been used for centuries in Ayurvedic medicine and in traditional Chinese medicine, primarily as an anti-inflammatory and wound-healing agent for musculoskeletal conditions, joint pain, and inflammatory disorders. It was used topically as a paste and internally as a decoction. Its application specifically to nerve entrapment conditions is not documented in classical texts; the modern interest in CTS reflects contemporary investigation of its active constituent, curcumin, in neuropathic and inflammatory contexts.

Scientific Evidence

A prospective, 8-week, randomized, placebo-controlled, parallel-group clinical trial assessed curcumin gel on CTS. A total of 70 patients were analyzed; the intervention group (n=35) received a topical curcumin gel and a night wrist splint, and the control group (n=35) received a placebo gel and a night wrist splint for 8 weeks. Outcomes were assessed using the Boston Carpal Tunnel Questionnaire and electrodiagnostic testing at baseline and after 8 weeks. The study concluded that curcumin gel could be effective in the improvement of symptom severity and daily activity of patients with CTS. This is described as one of the first investigations of curcumin for CTS specifically; the evidence is therefore very preliminary.

A study of 180 CTS patients scheduled for surgical decompression investigated oral supplementation with alpha-lipoic acid, curcumin phytosome, and B-group vitamins: controls received no treatment; Group B received supplementation before and after surgery for 6 months total; Group C received supplementation only before surgery for 3 months. Patients in Group B showed significantly lower nocturnal symptoms scores compared with controls at both 40 days and 3 months after surgery (P < 0.05), and had a significantly lower number of positive Phalen's tests at 3 months compared with the other study groups (P < 0.05).

It is important to note that in combination-product studies, the independent contribution of curcumin cannot be isolated. Evidence for curcumin alone in CTS is limited to one small topical trial and its inclusion in multi-ingredient studies. Overall evidence strength: preliminary.

Omega-3 Fatty Acids (Fish Oil / EPA and DHA)

Traditional Use

Populations with high fish-based diets, including those in Nordic and coastal Asian cultures, have historically consumed omega-3-rich foods, and fish oils have been used in various traditional medical systems for joint and inflammatory conditions. No classical tradition specifically identified omega-3s in relation to nerve entrapment neuropathies; modern interest is mechanistic, based on omega-3s' roles in reducing inflammatory eicosanoids and in supporting myelin integrity.

Scientific Evidence

A case series investigated patients with neuropathic pain, including one with carpal tunnel syndrome, who were treated with high oral doses of omega-3 fish oil (2,400–7,200 mg/day of EPA-DHA). Outcome measures included the short-form McGill Pain questionnaire, grip strength, and EMG nerve conduction studies. These patients had clinically significant pain reduction and improved function up to as much as 19 months after treatment initiation. Case series data are low on the evidence hierarchy; they are hypothesis-generating rather than conclusive.

A randomized, placebo-controlled trial of curcumin, fish oil, and alpha-lipoic acid in patients with carpal tunnel syndrome was published in BMC Musculoskeletal Disorders in 2022 (PMID 35236316), representing one of the few RCTs to examine fish oil in a CTS-specific cohort. In multi-ingredient studies, independent omega-3 effects again cannot be isolated. Evidence for omega-3s specifically in CTS remains weak and indirect; the broader neuropathic pain literature provides greater mechanistic context than CTS-specific trials.

B-Vitamin Complex (B1/Thiamine, B12/Methylcobalamin)

Scientific Evidence

Beyond the extensive pyridoxine (B6) literature, B1 and B12 are incorporated in combination neurotropic products studied in CTS. B-complex vitamins have been suggested for symptoms of carpal tunnel, and some studies indicate that low levels of riboflavin (vitamin B2) in the blood are associated with carpal tunnel syndrome and other inflammatory diseases.

A nutraceutical composed of alpha-lipoic acid, N-acetyl-L-carnitine, curcumin, vitamins B, E, and C showed significant clinical effects for CTS in maintaining outcomes at follow-up, demonstrating a positive association with the use of physical therapy as extremely low-frequency electromagnetic fields. This multi-ingredient study limits conclusions about individual B vitamins. Evidence for individual non-B6 B-vitamins in CTS is indirect and preliminary.

Bromelain (from Ananas comosus)

Traditional Use

Bromelain is an enzyme mixture derived from pineapple stem and fruit (Ananas comosus) that has been used in folk medicine traditions of Central and South America for inflammation, bruising, and wound healing. Its application to joint and musculoskeletal disorders reflects both traditional anti-inflammatory usage and modern enzyme-therapy research.

Scientific Evidence

Bromelain (Ananus comosus) has been listed in complementary medicine references for CTS for pain and inflammation. No dedicated high-quality clinical trials of bromelain monotherapy in CTS were identified in the peer-reviewed literature. Its inclusion in CTS references reflects its general anti-inflammatory mechanism rather than condition-specific RCT data. Evidence in CTS specifically: insufficient/unestablished.

Acetyl-L-Carnitine (ALCAR)

Scientific Evidence

Acetyl-L-carnitine has been studied as a potential treatment for CTS. It may help to reduce CTS-related pain and inflammation by increasing nerve conduction speed and reducing oxidative stress in the wrist. Additionally, ALCAR may help regenerate damaged nerves, which could improve nerve function in CTS sufferers. This proposed mechanism draws from broader neuropathy research. ALCAR has appeared as a component of combination nutraceuticals in CTS trials (e.g., alongside ALA and curcumin), but standalone RCT evidence specifically in CTS is limited. Evidence strength: preliminary, largely derived from combination-product studies.

Dietary and Lifestyle Factors

Obesity, Body Weight, and Diet Quality

A Mendelian randomization study found that genetically proxied higher BMI was positively correlated with CTS risk (OR 1.66, 95% CI 1.39–1.97), providing stronger-than-observational causal inference. A literature review also concluded that CTS is associated with age, female sex, and high BMI. Dietary factors that drive obesity and metabolic syndrome are therefore indirectly — and likely causally — relevant to CTS risk.

Blood Sugar Regulation and Refined Carbohydrates

Diabetes mellitus, through microvascular damage, nerve ischemia, and glycation-related connective tissue changes, may exacerbate CTS risk and severity. Genetically proxied type 2 diabetes significantly increased CTS risk (OR 1.17, 95% CI 1.07–1.29). From a nutritional standpoint, dietary patterns that contribute to insulin resistance and poor glycemic control are therefore of relevance to CTS risk through their effects on diabetic neuropathy pathways.

Inflammation and Dietary Pattern

Central deposition of obesity is the main component of metabolic syndrome and is associated with higher cardiovascular, diabetes, cancer, and overall mortality. Visceral adipose cells secrete IL-6 and plasminogen activator inhibitor 1 and display an unbalanced adipokine profile with higher leptin and resistin and lower adiponectin. These inflammatory mediators are biologically plausible contributors to synovial and connective tissue changes in the carpal tunnel, linking diet-driven metabolic dysregulation to CTS pathophysiology.

Occupational Ergonomics and Physical Activity

CTS as an occupational disease is driven by its epidemiological patterns, risk factors, symptoms, and management options, particularly emphasizing its relevance in professional environments. The complex interaction of anatomical, biomechanical, and pathophysiological factors underlines the critical role of ergonomic measures, prompt clinical identification, and tailored treatment plans in reducing its effects.

Smoking as a Modifiable Lifestyle Factor

Constitutional risk factors for CTS encompass obesity and smoking. In a large case-control study, the odds ratio for smoking as a risk factor for CTS was 4.862 (95% CI 3.991–5.925). Tobacco use is therefore a significant, modifiable lifestyle factor associated with CTS across population studies.

Hormonal and Fluid-Regulatory Factors

The risk of developing CTS is more likely when the carpal tunnel is modified, fluid equilibrium within the body is altered, or direct neuropathic factors are present. Pregnancy-related fluid retention and hormonal changes are well-documented contributors, as are conditions such as hypothyroidism, which may influence fluid balance and connective tissue composition.

Summary of Evidence Strength

• Vitamin B6 (Pyridoxine): Mixed. Biochemical rationale established (EGOT deficiency marker); clinical trial results inconsistent. Not supported as sole treatment for idiopathic CTS by current evidence consensus.
• Vitamin D: Preliminary to moderate. Observational data show higher deficiency prevalence in CTS patients; systematic reviews of supplementation trials report favorable but non-standardized outcomes. RCTs are needed.
• Alpha-Lipoic Acid: Moderate, particularly perioperatively. Meta-analysis shows improvement in functional scores and motor latency; sensory conduction not significantly improved. Most evidence is from small trials.
• Curcumin: Preliminary. One topical RCT and several multi-ingredient combination studies. Cannot isolate curcumin's independent contribution in combination trials.
• Omega-3 Fatty Acids: Weak in CTS specifically. Mechanistic rationale (anti-inflammatory, membrane support) is well-established in broader neuropathy literature; CTS-specific evidence is limited to case reports and combination RCTs.
• B-Complex (B1, B12): Indirect evidence from neurotropic combination products. Independent contributions not established in CTS-specific trials.
• Bromelain: Insufficient. No dedicated CTS clinical trials identified. Mechanistic rationale based on anti-inflammatory enzyme activity.
• Acetyl-L-Carnitine: Preliminary. Appears in combination nutraceutical studies; no standalone RCT evidence specifically for CTS identified.

References

• Assmus H, et al. Carpal tunnel syndrome – Part I (anatomy, physiology, etiology and diagnosis). PMC.
• Wipperman J, Goerl K. Carpal Tunnel Syndrome. StatPearls / NCBI Bookshelf (PMC3554258).
• Wipperman J, Goerl K. Carpal Tunnel Syndrome. StatPearls – NIH Bookshelf (NBK448179).
• Al-Rashidi M, et al. Retrospective Analysis of Carpal Tunnel Syndrome: Clinical Profile, Demographics, and Risk Factors. PMC12296892.
• Zeng Y, et al. Obesity, Type 2 Diabetes, and the Risk of Carpal Tunnel Syndrome: A Two-Sample Mendelian Randomization Study. PMC8339995.
• Dumitru M, et al. The Pathological Links between Adiposity and the Carpal Tunnel Syndrome. PMC9221759.
• Nowak W, et al. Risk factors for carpal tunnel syndrome. Journal of Polish Clinical Case Reports.
• Karpitskaya Y, Novak CB, Mackinnon SE. Prevalence of Smoking, Obesity, Diabetes Mellitus, and Thyroid Disease in Patients with Carpal Tunnel Syndrome. PMC1496575.
• Wang G, et al. Case-control study on individual risk factors of carpal tunnel syndrome. PMC5867472.
• Bekkelund SI, et al. Assessment of the Presence of Carpal Tunnel Syndrome in Patients with Diabetes Mellitus, Hypothyroidism and Acromegaly. PMC4525537.
• Gebrye T, et al. Global and Regional Prevalence of Carpal Tunnel Syndrome: A Meta-Analysis Based on a Systematic Review. PMC11645257.
• Milczarek C, et al. Carpal Tunnel Syndrome: A Comprehensive Review. Cureus / PMC12569720.
• Jacobson MD, Plancher KD, Kleinman WB. Vitamin B6 (pyridoxine) therapy for carpal tunnel syndrome. Hand Clin. 1996. PMID 8724577.
• Folkers K, et al. Biochemical evidence for a deficiency of vitamin B6 in the carpal tunnel syndrome based on a crossover clinical study. PMC392786.
• Ellis JM, et al. Response of vitamin B-6 deficiency and the carpal tunnel syndrome to pyridoxine. PubMed PMID 6961425.
• Aufiero E, et al. Carpal tunnel syndrome and vitamin B6. PMC1949298.
• Kasapoglu Aksoy M, et al. Effect of vitamin B6 on clinical symptoms and electrodiagnostic results of patients with carpal tunnel syndrome. PubMed PMID 24312849.
• Anusitviwat C, et al. The effects of vitamin D supplementation in carpal tunnel syndrome treatment outcomes: a systematic review. PMC8421488.
• Nasehi MM, et al. The Role of Vitamin D in Carpal Tunnel Syndrome Risk and Supplementation Outcomes: A Systematic Review. PubMed PMID 37151171.
• Cakmak S, et al. Carpel tunnel syndrome: A link with vitamin D and calcium. PMC7391289.
• Bhardwaj P, et al. Evaluation of Functional and Symptomatic Outcomes After Vitamin D3 Administration in Carpal Tunnel Syndrome With Hypovitaminosis D. PMC9608297.
• Guízar EAM, et al. Effect of Alpha-Lipoic Acid on Clinical and Neurophysiologic Recovery of Carpal Tunnel Syndrome: A Double-Blind, Randomized Clinical Trial. J Med Food. 2018. PMID 29356576.
• Boriani F, et al. Alpha-lipoic Acid After Median Nerve Decompression at the Carpal Tunnel: A Randomized Controlled Trial. J Hand Surg Am. 2017. PMID 28249792.
• Rahmawati D, et al. Efficacy of alpha-lipoic acid for the treatment of carpal tunnel syndrome: A systematic review and meta-analysis of randomized controlled trial studies. JAPS.
• Pajardi G, et al. Clinical Usefulness of Oral Supplementation with Alpha-Lipoic Acid, Curcumin Phytosome, and B-Group Vitamins in Patients with Carpal Tunnel Syndrome Undergoing Surgical Treatment. PMC3915925.
• Soo Khean G, et al. Evaluating the efficacy and tolerability of the oral combination of alpha lipoic acid and vitamin B complex preparation in carpal tunnel syndrome: a single center, randomized, double-blind, placebo-controlled trial. PubMed PMID 41361445.
• Abbasi H, et al. Efficacy of topical curcumin on mild to moderate carpal tunnel syndrome: a randomized double-blind, placebo-controlled clinical trial. PubMed PMID 38281082.
• Notarnicola A, et al. Efficacy of dietary supplement with nutraceutical composed combined with extremely-low-frequency electromagnetic fields in carpal tunnel syndrome. PMC6016299.
• Ko GD, et al. Omega-3 Fatty Acids for Neuropathic Pain: Case Series. ResearchGate / Clin J Pain. 2010.
• Frontiers in Public Health. Occupational Carpal Tunnel Syndrome: a scoping review of causes, mechanisms, diagnosis, and intervention strategies. 2024.
• American Academy of Orthopaedic Surgeons (AAOS). Carpal Tunnel Syndrome. OrthoInfo.